Latest news with #GO-4
Business Wire
22-05-2025
- Automotive
- Business Wire
Forsee Power Equips OEM Westward Industries
PARIS--(BUSINESS WIRE)--Regulatory News: Forsee Power (FR0014005SB3 – FORSE), the expert in smart battery systems for commercial and industrial electric vehicles, announces that it will equip light electric vehicle manufacturer Westward Industries with its battery systems. Serial production of Forsee Power battery systems for Westward will start in Hilliard, Ohio during the second quarter of 2025. Westward Industries, innovating zero-tailpipe-emission light utility trucks for on-road and off-road operations Westward Industries is a North American manufacturing company, specializing in the production of compact utility vehicles. The company has developed a reputation for manufacturing vehicles tailored for various sectors, including municipal services, industrial operations, and agriculture. The company's flag ship model, the GO-4 Interceptor, was at first only available as a gas-powered vehicle, but back in 2014 they started their transition to electromobility and now offer a wide choice of electric options for the GO-4 along with a new 100% electric vehicle series the MAX-EV with zero-tailpipe-emissions and quiet operations. The MAX-EV series is a robust, 100%-battery light electric utility truck available in on-road and off-road versions with various configurations, including open box, dump box, and cargo box, catering to diverse utility needs. Categorized as a low-speed vehicle (LSV), the on-road model is limited to 25 mph (40 km/h) and suitable for roads marked 35 mph or less. Westward Industries has selected Forsee Power's ZEN 8 SLIM, a 48V battery pack capable of operating alone or in parallel with other packs, to power some of their new 2025 vehicle models. Forsee Power, the unrivalled leader in battery systems for commercial and industrial vehicles Westward will arrange from one to four battery packs on a vehicle depending on customer preference and vehicle workload requirements. The Forsee ZEN 8 SLIM batteries embed 8 kWh per pack, allowing the vehicles to operate autonomously up to a 200km max range with a 3x battery pack configuration. ZEN 8 SLIM has been designed to electrify off-highway and light vehicles in a 100%-battery mode. The batteries are only 128 mm thick and can be integrated both vertically and horizontally. The pack is available both as a stand-alone 48V system with its own embedded battery management system (BMS), as employed by Westward Industries. It can also be delivered as a 48V or 72V module in series with an external BMS, to allow use at system voltages up to 800V. ZEN 8 SLIM batteries offer an excellent energy density of 251 Wh/L – among the best on the market – to ensure all-day operations in one single charge, a very long life of 5,000 cycles, and IP67 certified for resistance to air and water. To date, Forsee Power has powered over 145,000 light electric vehicles and 4,500 electric buses globally, cementing its position as the leading non-Chinese innovator in battery systems for the market industrial and commercial vehicles market. The Forsee Power battery packs for Westward Industries will be added to existing production of the pack for a broad base of customers, currently available from Forsee Power's Columbus-area facility with Buy America compliance. About Forsee Power Forsee Power is an industrial group specializing in smart battery systems for sustainable electric transport (light vehicles, off-highway vehicles, buses, trucks, and trains). A major player in Europe, Asia and North America, the Group designs, assembles, and supplies energy management systems based on cells that are among the most robust in the market and provides installation, commissioning, and maintenance on site and remotely. More than 4,500 buses and 145,000 LEV have been equipped with Forsee Power's batteries. The Group also offers financing solutions (battery leasing) and second-life solutions for transport batteries. Forsee Power and its 750 employees are committed to sustainable development and the Group has obtained the Gold medal from leading sustainability rating agency EcoVadis. For more information: | @ForseePower
Yahoo
13-05-2025
- Business
- Yahoo
General Oncology to Participate in Three Upcoming Conferences
BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class treatments for metastatic cancers, today announced that members of its senior management team will participate in three upcoming conferences in May and June 2025: Pharma Partnering US SummitLocation: San Diego Marriot Del Mar, CACompany Presentation: Abid Ansari (CFO)Date and Time: Thursday, May 15, 11:00 – 11:20 a.m. PT American Society of Clinical Oncology (ASCO) 2025 Annual MeetingLocation: McCormick Place, Chicago, ILBooth 24156: Jeff Glazier (CEO), Abid Ansari (CFO), and Arnold Glazier, M.D. (CSO)Date: May 30 – June 3 BIO International ConventionLocation: Boston Convention & Exhibition Center, MABooth 3578: Jeff Glazier (CEO) and Abid Ansari (CFO)Date: June 16 – 19 About General Oncology, Inc. General Oncology is a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers. The company is developing GO-4, an investigational therapy for metastatic cancers, currently completing the phase 1 SHARON trial (NCT04150042) for metastatic cancers in the setting of a BRCA1/2 or PALB2 mutation. With a commitment to innovation, General Oncology is focused on advancing transformative therapies for cancer patients. For more information about General Oncology, please visit Investor Contact:Abid Ansari(617) 468-4646ir@ Media Contact:Madelin Hawtinmhawtin@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-04-2025
- Business
- Yahoo
General Oncology Appoints Seasoned Biotech Executive Abid Ansari as Chief Financial Officer
BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers, today announced the appointment of Abid Ansari as Chief Financial Officer (CFO). Abid brings over 20 years of experience in the biotechnology sector with expertise in financial strategy and corporate development for public and private life science companies. He has led multiple successful capital-raising initiatives, including initial public offerings (IPOs) and large-scale private funding rounds, and has extensive experience with business development transactions, including merger and acquisition agreements and in-licensing/out-licensing deals. 'We are excited to welcome Abid to our executive team,' said Jeff Glazier, Chief Executive Officer of General Oncology. 'With deep expertise in strategic financial leadership, capital raising, and business development, Abid is exceptionally well-suited to help drive our financial strategy as we advance our pipeline. His leadership will be instrumental in securing a strong foundation to support our next phase of growth, including our upcoming clinical readout and a potentially pivotal trial, and ultimately delivering on our mission to bring innovative therapies to cancer patients in need.' Mr. Ansari said, 'I am thrilled to join General Oncology as the Company advances its proprietary treatment in metastatic pancreatic cancer. This is a critical and exciting moment in the Company's journey. I look forward to working with the leadership team to ensure we are well-positioned financially to drive innovation and deliver transformative therapies.' Abid Ansari brings over 20 years of experience in the biotechnology and life sciences industries, including eight years as a CFO. He has successfully raised over $450M through equity transactions, including a $153M Series C at Artios and a $146M IPO at Precision BioSciences. Earlier in his career, Abid held positions at GlaxoSmithKline (GSK) in deal finance and portfolio management. While at GSK, he played a key role in the acquisition of Bristol Myers Squibb's HIV portfolio, the asset sale of ofatumumab to Novartis, and a strategic research collaboration and licensing agreement with Adaptimmune. Additionally, Mr. Ansari previously held commercial and capital finance roles at MedImmune. Mr. Ansari graduated from Purdue University with a Bachelor of Science in Chemical Engineering and a Master of Business Administration. He is a Certified Public Accountant in the state of Delaware. About General Oncology, Inc. General Oncology is a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers. The company is developing GO-4, an investigational therapy for metastatic cancers, currently completing the phase 1 SHARON trial (NCT04150042) for metastatic cancers in the setting of a BRCA1/2 or PALB2 mutation. With a commitment to innovation, General Oncology is focused on advancing transformative therapies for cancer patients. For more information about General Oncology, please visit Investor Contact: Abid Ansari (617) 468-4646 ir@ Media Contact: Madelin Hawtin mhawtin@ in to access your portfolio
